Overview

Join Dr Prince Otchere (University of Texas Health, US), Prof Daniel Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) in this week’s IC-OS broadcast as they delve into research unveiling a cardiac risk prediction model tailored for patients battling HER-2 positive breast cancer undergoing Trastuzumab therapy. This innovative model represents a significant stride in personalised healthcare, offering precise risk assessment tools crucial for patient safety and well-being. Stay tuned for insights from leading experts and the potential impact on clinical practice and patient care.

Dr Otchere will be presenting an article, published in the Cardio-Oncology journal, that was selected as the winner of the journal’s manuscript competition.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.